Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
CytoDyn
AddedFeb 21, 2024
UpdatedJul 3, 2026
CytoDyn

CytoDyn

Public

CytoDyn Inc., a global biotech firm, specializes in developing innovative viral treatments, particularly for HIV.

HQ
Vancouver, WA, US
Founded
2002
Overview
Compare
Fundraising
Employees
Website

CytoDyn Inc., founded with a mission to revolutionize viral treatment, is a biotechnology company specializing in developing innovative therapies for human immunodeficiency virus (HIV). The company aims to improve the quality of life for patients worldwide through cutting-edge scientific research and development. CytoDyn's flagship product, Leronlimab, is a monoclonal antibody designed to treat HIV by blocking the CCR5 receptor, which HIV uses to enter cells. Their market focus includes not only HIV but also other potential viral infections and cancer.

Notable figures affiliated with CytoDyn include key scientists and industry experts who have contributed to its research and development efforts. The company has attracted significant investment from various stakeholders in the biotech industry, underscoring its potential impact. Among its key achievements, CytoDyn has advanced Leronlimab through multiple clinical trial phases, demonstrating promising results in both efficacy and safety. The overall impact of CytoDyn's work lies in its potential to offer new hope and improved treatment options for millions of patients affected by HIV and other serious conditions globally.

CytoDyn - Similar Companies

Vir Biotechnology logo

Vir Biotechnology

vir.bio

CytoAgents logo

CytoAgents

cytoagents.com

Viriom logo

Viriom

viriom.com

Gilead Sciences logo

Gilead Sciences

gilead.com

Chimerix logo

Chimerix

Cynvec logo

Cynvec

cynvec.com

Cytodel logo

Cytodel

cytodel.com

Cydan logo

Cydan

cydanco.com

IconOVir Bio logo

IconOVir Bio

iconovir.com

Globavir Biosciences logo

Globavir Biosciences

RhinoCyte logo

RhinoCyte

rhinocyte.com

Cyclo Therapeutics logo

Cyclo Therapeutics

CytomX Therapeutics logo

CytomX Therapeutics

cytomx.com

Dynavax Technologies logo

Dynavax Technologies

dynavax.com

Vyriad logo

Vyriad

vyriad.com

CytoDyn - Quick Facts

Who are CytoDyn's competitors?

Companies similar to CytoDyn include Vir Biotechnology, CytoAgents, Viriom and Gilead Sciences.

When was CytoDyn founded?

CytoDyn was founded in 2002.

Where is CytoDyn's headquarters located?

CytoDyn's headquarters is located in Vancouver, WA, US.

When was CytoDyn's last funding round?

CytoDyn's most recent funding round was for $2.9M (USD) in September 2021.

How much has CytoDyn raised to-date?

As of Sep 15, 2021, CytoDyn has raised a total of $89.5M (USD).

How many employees does CytoDyn have?

CytoDyn has 12 employees as of Feb 6, 2024.

CytoDyn - Classification

Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Licensing
  • Recurring
  • Software
Customer
  • Enterprise
  • Government
Main Product
  • Viral Treatments
Tags
  • Biotech
Unique IDs
  • ein: 753056237
  • secCik: 0001175680
  • ticker: CYDY
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations
ISIC
  • 2100Manufacture of pharmaceuticals, medicinal chemical and botanical products
Show 17 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
  • 541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SIC
  • 9900Nonclassifiable Establishments
  • 4000Railroad Transportation
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research
ISIC
  • 7210Research and experimental development on natural sciences and engineering